Navigation Links
Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
Date:2/12/2009

LLC ("BHP"), an investment and merchant banking firm headquartered in New York City. Mr. Adelman has extensive financing and merger and acquisition experience, typically involving complex balance sheets and operational restructurings. Prior to founding BHP, Mr. Adelman was Managing Director of Investment Banking in the New York office of H.C. Wainwright & Company, Inc.

Mr. Adelman began his career at Coopers and Lybrand LLP where he worked in the financial services industry consulting practice, with a particular focus on the hedge fund industry. Mr. Adelman is also the co-founder and a Managing Member of Cipher Capital Partners, a private investment entity that has invested, through its managed accounts, approximately $250 million in capital since 2006. Mr. Adelman graduated from the University of Pennsylvania with a BA, cum laude, in Economics (1991) and graduated from Cornell Law School (1994), where he was Editor of the Cornell International Law Journal. Mr. Adelman also serves on the audit and compensation committees of Trio-Tech International, an Amex listed company. "Jason was a lead investment banker for Computer Motion. He was of major assistance on several of our pipe transactions and played a meaningful role in our successful merger agreement with Intuitive Surgical. He brings excellent experience and financial acumen to our Board," said Bob Duggan Chairman and CEO of Pharmacyclics.

About Pharmacyclics

Pharmacyclics(R) is committed to creating and developing novel pharmaceutical products that treat serious unmet medical needs in oncology and autoimmune diseases. Its deep and broad pipeline includes four innovative drug candidates that are currently under clinical development. The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at '/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Pharmacyclics Secures $5.0 Million in Debt Financing
2. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
3. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
4. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
5. Pharmacyclics Announces It Received Nasdaq Notification
6. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
7. Savient Announces Appointment of David Gionco as Chief Financial Officer
8. Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer
9. SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS
10. Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009
11. Cord Blood Announces $1 Million Reduction in Long Term Debt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... N.C. and PARIS ... firm AgBiome, and Genective, key developer of biotech ... the discovery of new generations of insect control ... insect control to counter the realities of advancing ... Genective, aligning AgBiome,s unique insect control technology with ...
(Date:7/1/2015)... 1, 2015   Decision Resources Group ... of Otezla are its oral administration, alternative mechanism ... by surveyed rheumatologists. Otezla was the first oral ... of active psoriatic arthritis in the ... care includes conventional oral treatments including disease-modifying antirheumatic ...
(Date:7/1/2015)... ... July 01, 2015 , ... The next-generation sequencing (NGS) clinical market is poised ... molecular diagnostics industry. BCC Research reveals in its new report that the market drivers ... and a growing need for better diagnostics as part of a molecular diagnostics trend. ...
(Date:7/1/2015)... BANGALORE, India , July 1, 2015  Strand ... next generation sequencing technology to empower cancer care, today ... as chief executive officer. In his expanded role as ... all strategy, business expansion and worldwide operations effective immediately.  ... Strand,s chairman and CEO since its founding in 2000, ...
Breaking Biology Technology:AgBiome and Genective collaborate to create novel insect-resistant crops 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3
... 29 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced today that ... GSK ) related to the designation as a development candidate of ... the drug to Phase 2 proof-of-concept, at which time GSK has the option ... , "We ...
... LONDON , July 29, 2010 ... Dr Neill Moray Mackenzie to the role of Chief,Executive ... of executive,board level management within the biotechnology and pharmaceutical ... (an LSE,listed company), Avidex Ltd (now Immunocore) and most ...
... July 28 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. ... Inc. (NASDAQ: ATHX) announced positive results from its ... cell therapy product, administered to individuals following acute ... a heart attack. The study results, which represent ...
Cached Biology Technology:Isis Earns $5 Million Milestone Payment From GSK for Designation of a Development Candidate to Treat an Undisclosed Rare and Serious Disease 2Isis Earns $5 Million Milestone Payment From GSK for Designation of a Development Candidate to Treat an Undisclosed Rare and Serious Disease 3CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO 2CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO 3CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO 4CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO 5Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 2Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 3Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 4Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 5Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 6Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 7Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 8Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 9
(Date:6/16/2015)... , June 16, 2015  With the increasing number ... remains a top concern. The recent compromise of ... need for strong authentication within government agencies. ... biometric one-time password (OTP) authenticator, has been submitted for ... 140-2 Level 3 validation for tamper proofing. ...
(Date:6/15/2015)... According to a new market research report ... Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) ... Natural Language Processing Market is expected to grow to ... forecast period 2015-2020. Browse 65 market ...   through 155 P ages and in-depth TOC ...
(Date:6/12/2015)... 12, 2015  Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring, announced the ... electronically capture, analyze and identify participants of a ... This system can: , ... and subsequent sign-on process is actually the person ...
Breaking Biology News(10 mins):Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2
... China - BGI, the world,s largest genomic organization, today ... superior performance of RNA-Seq in predicting patient outcomes as ... by the U.S. Food and Drug Administration (FDA). The ... of the MicroArray Quality Control (MAQC), aimed at assessing ...
... Each year about 3300 Australian men die of ... men, matching the impact of breast cancer on women. ... removal of the prostate, radiation, freezing the tumour or ... are often side-effects including incontinence and impotence. Growing ...
... Mass., Nov. 2, 2011 VeCommerce Incorporated, a ... the recent completion of a management buyout from ... business as SimplySay, specializes in communications and speech ... services, insurance, and pari-mutuel wagering. ...
Cached Biology News:BGI to play a pivotal role in demonstrating the superior performance of RNA-Seq 2Starving prostate cancer 2VeCommerce Inc. Becomes SimplySay 2
... White crystalline solid. PACKAGED UNDER ... Contaminants: DNases, proteases, RNases: none ... nm): ≤0.500; (100 mM, 1 cm, 280 ... Soluble in H 2 O. RTECS ...
... Genome ChIP-on-chip Microarray is specifically designed ... cerevisiae) DNA binding proteins by pairing ... microarrays. This set delivers robust hybridization ... true binding events and fewer false ...
... Salmonella genomes has allowed the development of ... pairs. The S. enterica Typhimurium (strain LT2) ... bp; 4,440 ORFs) and a plasmid, pSLT ... Sigma-Genosys have been designed to amplify all ...
... productivity and allows you to achieve a higher ... beyond traditional paper-based weighing processes into a powerful ... Control of ... PR, SR, PG-S, PG, SG, AT, MT, UMT, ...
Biology Products: